ClinicalTrials.gg
CompletedNCT02090764Updated Aug 20, 2024Results posted

Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

A Phase 3 interventional study of Ozenoxacin and Placebo in Impetigo, sponsored by Ferrer Internacional S.A.. Completed at 1 site in Puerto Rico. Open to participants aged 2 Months and older. Per ClinicalTrials.gov, last updated 2024-08-20.

Sponsored by Ferrer Internacional S.A. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
412
Allocation
Randomized
Ages
2 Months and older
Sex
All
01

Study summary

This is multicenter, randomised, placebo controlled, parallel, double blinded , superiority clinical study comparing ozenoxacin cream versus placebo, in patients with a clinical diagnosis of non-bullous or bullous impetigo.

02

Conditions studied

  • Impetigo

Browse trials for

03

In context

Impetigo

30 studies on the registry are indexed under Impetigo; 3 are open to participants now.

This study's enrollment of 412 is above the median of 255 across 24 interventional studies indexed under Impetigo.

Browse Impetigo studies →

Lead sponsor

Ferrer Internacional S.A. is the lead sponsor of 21 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of bullous or non bullous impetigo. The patient has a total affected area comprised between 1-100 cm2 with surrounding erythema not extending more than 2 cm from the edge of any affected area. In case of multiple affected areas the total area will be the sum of each affected area and will not exceed 100 cm2. Additionally for patients \< 12 years the total area will not exceed a maximum of 2% of the body surface area.
  • Total Skin Infection Rating Scale (SIRS) score of at least 3, including pus/exudate score of at least 1

Exclusion criteria

Exclusion Criteria:

  • Has a bacterial infection, which in the opinion of the investigator, could not be appropriately treated by a topical antibiotic.
  • Has systemic signs and symptoms of infection (e.g. a fever; defined as an axillary temperature over 37.2 °C (99.0 °F)
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
412 participants (actual)

Study arms

  • Experimental
    Ozenoxacin

    ozenoxacin cream 1%

    Drug: Ozenoxacin

  • Placebo comparator
    Placebo

    Placebo cream

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical Success

    Clinical response (clinical success or clinical failure) at end of therapy (Visit 3) in the intent to treat clinical (ITTC) population. Clinical success at V3 was defined as: SIRS score 0 for blistering, exudates/pus, crusting and itching/pain and no more than 1 for erythema/inflammation such that no additional antimicrobial therapy in the baseline (Visit 1) affected area is necessary. The skin infection rating scale (SIRS) is a severity index based on five signs or symptoms: blistering, exudate/pus, crusting, erythema/inflammation, itching/pain.

    Time frame: Visit 3 (Day 6-7)

07

Results

Posted May 19, 2016

Participant flow

Patients were enrolled at 34 sites in Germany, Puerto Rico, Romania, Russia, South Africa, Spain and the United States of America (USA).

Participant flow — Overall Study
MilestoneOzenoxacinPlacebo
Started206206
Completed200186
Not completed620
Withdrew: Adverse event13
Withdrew: Lack of efficacy013
Withdrew: Withdrawal by subject21
Withdrew: Intercurrent illness and other11
Withdrew: Lost to follow-up22

Outcome measures

PrimaryClinical Success

Clinical response (clinical success or clinical failure) at end of therapy (Visit 3) in the intent to treat clinical (ITTC) population. Clinical success at V3 was defined as: SIRS score 0 for blistering, exudates/pus, crusting and itching/pain and no more than 1 for erythema/inflammation such that no additional antimicrobial therapy in the baseline (Visit 1) affected area is necessary. The skin infection rating scale (SIRS) is a severity index based on five signs or symptoms: blistering, exudate/pus, crusting, erythema/inflammation, itching/pain.

Time frame:
Visit 3 (Day 6-7)
Reported as:
Number · percentage of Participants
Clinical Success
percentage of ParticipantsOzenoxacinPlacebo
Clinical Success55.239.2
Statistical analysis
  • Ozenoxacin vs Placebo · Chi-squared · p = 0.001

Adverse events

Collected over AEs were elicited from signing the informed consent to the completion of the clinical study (including the Follow up Visit) or premature patient withdrawal from the study. (10-13 days). Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ozenoxacin—0/206 (0%)0/206 (0%)
Placebo—0/205 (0%)0/205 (0%)

Baseline characteristics

Baseline analysis population was consider the safety population. Safety population was defined as all patients who received at least one application of study drug. One patient was randomised to placebo but never treated.

Age, Customized
Age, Customized(participants)OzenoxacinPlaceboTotal
>=18 years6970139
>=12 years to <18 years232346
>= 2 months to <12 years114112226
Sex: Female, Male
Sex: Female, Male(Participants)OzenoxacinPlaceboTotal
Female94107201
Male11298210
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)OzenoxacinPlaceboTotal
Caucasian122139261
Black533891
Asian161531
Mixed Race151328
Region of Enrollment
Region of Enrollment(participants)OzenoxacinPlaceboTotal
Puerto Rico232346
Germany211637
Romania262652
Russian Federation273057
South Africa433477
Spain123
United States6574139
08

Study locations

1 site
  • Caparra Internal Medicine Center
    Rio Grande, Puerto Rico
09

References and documents

Publications

  • Hebert AA, Albareda N, Rosen T, Torrelo A, Grimalt R, Rosenberg N, Zsolt I, Masramon X. Topical Antibacterial Agent for Treatment of Adult and Pediatric Patients With Impetigo: Pooled Analysis of Phase 3 Clinical Trials. J Drugs Dermatol. 2018 Oct 1;17(10):1051-1057. PubMed 30365584 ↗
  • Rosen T, Albareda N, Rosenberg N, Alonso FG, Roth S, Zsolt I, Hebert AA. Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial. JAMA Dermatol. 2018 Jul 1;154(7):806-813. doi: 10.1001/jamadermatol.2018.1103. PubMed 29898217 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2014
First posted
Mar 18, 2014
Start
Jun 2014
Primary completionActual
May 2015
CompletionActual
May 2015
Results first posted
May 19, 2016
Last update
Aug 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02090764
Responsible party
Sponsor
First posted
Mar 18, 2014
Start date
Jun 2014
Primary completion
May 2015
Completion
May 2015
Results posted
May 19, 2016
Last update
Aug 20, 2024

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ozenoxacin

Start the discussion